This document discusses bronchial asthma and acute asthma. It defines bronchial asthma as a heterogeneous disease characterized by chronic airway inflammation and variable, reversible airflow limitation. Epidemiological data shows the global prevalence of asthma among school-aged children is around 10%. The document then discusses clinical phenotypes of asthma and common symptoms. It provides guidelines on managing asthma including drug therapy for different age groups, monitoring issues, and managing acute exacerbations. It also includes a case scenario of a 5-year-old boy presenting with worsening asthma symptoms and outlines his diagnosis, initial management, and long-term treatment plan.
This document discusses bronchial asthma and acute asthma. It defines bronchial asthma as a heterogeneous disease characterized by chronic airway inflammation and variable, reversible airflow limitation. Epidemiological data shows the global prevalence of asthma among school-aged children is around 10%. The document then discusses clinical phenotypes of asthma and common symptoms. It provides guidelines on managing asthma including drug therapy for different age groups, monitoring issues, and managing acute exacerbations. It also includes a case scenario of a 5-year-old boy presenting with worsening asthma symptoms and outlines his diagnosis, initial management, and long-term treatment plan.
This document discusses bronchial asthma and acute asthma. It defines bronchial asthma as a heterogeneous disease characterized by chronic airway inflammation and variable, reversible airflow limitation. Epidemiological data shows the global prevalence of asthma among school-aged children is around 10%. The document then discusses clinical phenotypes of asthma and common symptoms. It provides guidelines on managing asthma including drug therapy for different age groups, monitoring issues, and managing acute exacerbations. It also includes a case scenario of a 5-year-old boy presenting with worsening asthma symptoms and outlines his diagnosis, initial management, and long-term treatment plan.
SYMPTOMS SUCH AS WHEEZE, SHORTNESS OF BREATH, CHEST TIGHTNESS AND COUGH THAT VARY OVER TIME AND INTENSITY TOGETHER WITH VARIABLE AIRFLOW LIMITATION Reversible and variable airflow limitaton as evidenced by >15% improvement in PEFR (Peak Expiratory Flow Rate), in response to administraton of a bronchodilator EPIDEMIOLOGY •The Internatonal Studies on Asthma And Allergy (ISAAC) has shown that the prevalence of asthma among school age children is 10% •According to National Health and Morbidity Survey 2011, the prevalence of asthma in Malaysia is at 6.3%. CLINICAL PNENOTYPES •ALLERGIC ASTHMA •NON ALLERGIC ASTHMA •ADULT ONSET •ASTHMA WITH PERSISTANT AIRFLOW LIMITATION •ASTHMA WITH OBESITY • recurrent or persistent non-productve cough that worsens atnight or accompanied by wheezing or breathlessness. occurring in the absence of COUGH respiratory infectons, usually with laughing, crying or exposure to tobacco smoke.
• Recurrent wheezing during sleep or with triggers such as
actvity, laughing, crying or exposure to tobacco smoke or air polluton Wheezing
• not running, playing, or laughing at the same intensity
Reduced actvity: as other children
• Past or family history of allergic disease or history of asthma in frst
Family degree relatve. history Management Drug therapy AGE ORAL MDI+ MDI + MASK DRY PER SPACER + SPACER INHALER <5 + + - - 5- 8 - + - - >8 - + + + Monitoring 3 issues 1. assessment of asthama control 2. compliance to asthma therapy 3. asthma education Management on acute exacerbation of asthma 1. Initial assessment+ short history: ◦ trigger factors ◦ diagnosis ◦ severity: monitir pulse, colour, PEER, ABG and SPO2 (close monitor for at least 4 hours) 2. hydration- fluid maintenance 3.role of aminophylline 4.IV Mg SO4 Case Scenario X, 5 years old boy was brought by his mother to clinic. he was known case of bronchial asthma which diagnosed 2 years ago. He presented with rapid breathing for 2/7, cough for 1/52 and wheeze for x 1/7. His mother noticed that his son worsening cough for this month. He has morning cough / nigh cough almost 2 times a week. he also visit nearest GP last month due to shortness of breath. further history, he was admitted to Hospital last year for AEBA secondary to bronchopneumonia. he usually require nebulisation 2- 3 monthly. trigerring factors : URTI and dust. otherwise, he can play well with neighbour kids, running around. occasionally he will have catching breath episode. but mother claimed resolved after rest. Family history suggestive of brochial asthma- father had childhood asthma and his mother has allergic rhinitis. father is a cigrate smoker. there was a golden retriever in his house. Currently , he is on MDI Salbutamol 2pff PRN & MDI budesonide 200mg BD what will you do ? The boys is talking to you comfortably, pink, sit in decubitus. Pulse. 108 BP :95/75 T. 37 RR: 40 SPO2: 96% under room air +mild SCR Throat: injected. tonsil not enlarged presence of ezema over flexor area of bilateral nads and legs harrison sulcus, hyperinflated chest Lungs: air entry equal, prolonged expiratory phase, +rhonchi, no crepitation CVS DRNM PA soft, liver palpable ( 2 finger breath) Diagnosis Mild AEBA secondary to URTI with underlying mild persistent bronchial asthma management: 1. put on Nasal Prong O2 2. Blood invastigation: FBC 3. CXR 4. neb subutamol 200mg STAT & reassessment long term plan: 1. icrease dose of MDI budesonide to 400mcg BD 2. avoild triggering factor 3. asthma action plan 4. follow up • reveiw patient month after initiation of preventrr or readjusting the dose of preventer. if remain stable after 3 months of treatment , it can be stepped down.